ASTROTECH Corp (ASTC)

Astrotech Corporation operates in the analytical instruments industry, commercializing its proprietary Astrotech Mass Spectrometer Technology platform through wholly owned subsidiaries. The company's mission encompasses advancing mass spectrometry and gas chromatography to enable precise detection and identification of chemical compounds across high-demand environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. The industry is characterized by rapid technological change, evolving standards, and intense competition, with the commercial lunar and space industries attracting significant competition from commercial entities and government-sponsored programs, many with substantially greater resources. The company also recently approved strategic initiatives focused on future lunar resource development, autonomous lunar industrial infrastructure, Moon-based advanced computing, semiconductor manufacturing, lunar power generation, mining, chemical manufacturing, product transportation, and equipment leasing opportunities on the Moon.

The company faces competition primarily from IMS-based explosive trace detectors, with competitors that are much larger and have well-established sales forces. In the industrial process control market, competitors include ABB, Siemens, Emerson, Thermo Fisher Scientific, Endress and Hauser, Perkin Elmer, Mettler Toledo, PAC LP, Horiba Process Analyzers, and AMETEK. For lunar initiatives, competitors include Space Exploration Technologies Corp. (SpaceX), Blue Origin, Intuitive Machines, and international space agencies. The company's competitive advantages include the TRACER 1000's near-zero false alarms, limitless library expansion, high uptime, and confirmatory technology, as well as the AgLAB 1000-D2's ability to improve ending-weight yields by 20% or more during field trials. The company believes it is the only provider of a mass spectrometry system for the hemp and cannabis distillation market, giving it a distinct advantage.

The company generates revenue through the sale of mass spectrometry and gas chromatography equipment, along with related accessories, consumables, and routine maintenance and warranty programs. Revenue is derived from both product sales and services, with a mix of transactional and recurring income. The company employs direct sales and channel sales through distributors across its business units. The core AMS Technology platform is licensed exclusively to five wholly owned subsidiaries for different fields of use: 1st Detect for security and detection, AgLAB for agriculture, BreathTech for breath analysis, Pro-Control for industrial process control, and EN-SCAN for environmental testing. The company also has a recently approved Lunar Power and Light Corporation initiative focused on lunar resource development, though it has not yet generated any revenue from these initiatives.

1st Detect Corporation manufactures the TRACER 1000, the world's first mass spectrometry-based explosive trace detector approved by the European Civil Aviation Conference and the U.S. Transportation Security Administration for air cargo. As of June 30, 2026, the TRACER 1000 has been deployed in approximately 37 locations in 16 countries. The product is designed to outperform IMS-based ETDs with near-zero false alarms and a virtually unlimited, easily expandable threat library. The TRACER 1000 received ECAC/EU G1 approval on May 11, 2026, and ECAC certification for wand swabbing on June 8, 2026. The company is also evaluating a potential sale of 1st Detect to provide additional capital for strategic initiatives.

AgLAB Inc. has developed the AgLAB 1000 series of mass spectrometers for the hemp and cannabis market, with initial focus on optimizing yields in distillation processes. The AgLAB 1000-D2 uses the Maximum Value Process solution to analyze samples in real-time and assist operators in maximizing yields. Field trials demonstrated improvements in ending-weight yields by 20% or more. BreathTech Corporation developed the BreathTest-1000 for breath analysis, but the pilot study with The Cleveland Clinic Foundation concluded and terminated on February 7, 2025, and the company has determined to deploy capital to other subsidiaries due to regulatory requirements. Pro-Control Inc. offers the Pro-Control 1000-D2 mass spectrometer for industrial process control applications. EN-SCAN Inc. manufactures and sells environmental testing instruments including the EN-SCAN Handheld GC, EN-SCAN Fenceline Monitor, and EN-SCAN Rugged Lab GC-MS, and announced the commercial launch of the Labrador HH-GC on May 21, 2026.

During the fiscal year, the company announced several significant developments. On May 11, 2026, the TRACER 1000 achieved ECAC/EU G1 approval. On June 8, 2026, the TRACER 1000 received ECAC certification for wand swabbing. On June 16, 2026, the Board authorized management to pursue a potential sale process of 1st Detect. On May 21, 2026, the company announced the commercial launch of the Labrador HH-GC. The company also initiated a lease program with SC Labs as an example of a channel sales program for AgLAB. The Board approved strategic initiatives focused on lunar resource development, and the company entered into an at-the-market offering program, with a subsequent ATM offering agreement dated August 28, 2026.

For the fiscal year ended June 30, 2026, the company reported total revenues of $1,998,734, compared to $1,758,953 in the prior fiscal year. Net loss was $4,730,000, compared to a net loss of $4,730,000 in the prior year. The company's cash position and capital resources are detailed in the financial statements, with the company holding investments in corporate and government debt mutual funds and ETFs. The company's financial performance reflects its ongoing investment in research and development and the commercialization of its product lines.

A major growth vector is the potential sale of 1st Detect, which the Board authorized management to pursue on June 16, 2026, to provide additional capital for the announced strategic initiatives. The company is also focused on expanding the TRACER 1000's market reach, having achieved ECAC/EU G1 approval and ECAC certification for wand swabbing, which opens the customer base to include airports that require wand swabbing. The company is currently accepting orders for the TRACER 1000 ETD and NTD, and is listed on the GSA IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290, allowing sales to the U.S. federal government.

Another growth vector is the AgLAB product line, with the company planning to launch the AgLAB-1000-D1, an inline process control unit that will be integrated directly into distillation equipment. The company is also expanding its channel sales program, having initiated a lease program with SC Labs and planning to engage with additional channel partners in the hemp and cannabis market. The company believes the U.S. wholesale value of the cannabis crop from states permitting adult-use and medical cannabis exceeds $6 billion annually, indicating significant market potential. International markets present attractive future growth opportunities as the number of countries with legal recreational or medicinal use continues to expand.

The company's Lunar Initiatives represent a significant growth vector, with the Board approving strategic initiatives focused on lunar resource development, autonomous lunar industrial infrastructure, Moon-based advanced computing, semiconductor manufacturing, lunar power generation, mining, chemical manufacturing, product transportation, and equipment leasing. The company intends to evaluate and potentially develop infrastructure technologies that could support semiconductor processing, advanced computing systems, and quantum computing manufacturing operations on the lunar surface. However, these initiatives are in very early stages, with no formal business plan or capital budget approved, and the company currently does not have the cash or resources to fund the significant capital expenditures required.

The company's margin and cost outlook is influenced by its continued investment in research and development across its business units. The company is focused on developing derivative products, improving system functionality and reliability, optimizing design, reducing cost, and streamlining software and user experience. The company has determined to deploy capital to its other subsidiaries rather than BreathTech due to the significant investment and regulatory requirements needed for commercialization. The company expects to incur significant capital expenditures over a period of years before its Lunar Initiatives may become commercially scalable or profitable, which may never occur.

The company's operational outlook includes ongoing field trials with the TSA for the TRACER 1000 during Stage II testing, with the potential to be added to the 'qualified' list for long-term designation for permitted air-cargo screening use. The company has also started the process to pass TSA checkpoint testing, involving Developmental Test and Evaluation with the Transportation Security Laboratory. The company is expanding its sales efforts, with Pro-Control using direct sales with proof of concept and trial engagements, and EN-SCAN appealing to a wide range of industries. The company does not currently have employees with the technical expertise necessary to fully develop the Lunar Initiatives, and implementation will depend on technical validation, ability to attract and retain employees, customer demand, partnerships, lunar transportation, and sufficient financing.

The company's capital allocation strategy includes evaluating the potential sale of 1st Detect to provide additional capital for strategic initiatives. The company has an at-the-market offering program, with a subsequent ATM offering agreement dated August 28, 2026. The company's research and development expenses for the fiscal year ended June 30, 2026, were $1,998,734, compared to $1,758,953 in the prior year. The company does not currently have the cash or resources to fund the significant capital expenditures required for its Lunar Initiatives, and its ability to obtain financing will depend on factors beyond its control.

The company faces significant headwinds and constraints, including the adverse expectations regarding the global economy, inflation, the potential for recession, and geopolitical tensions. The company is also subject to uncertainty in government funding and support for key programs, grant opportunities, or procurements. The company's Lunar Initiatives are subject to significant technical complexity and risks, and the company currently does not have the technical expertise or operational capabilities to execute on any of them. The markets the company intends to enter are expected to attract significant competition from entities with substantially greater resources, and the award processes for government programs such as the Appendix A Program and NASA's CLPS2 Program are highly competitive and influenced by factors beyond the company's control.

Management's message emphasizes the company's commitment to commercializing its AMS Technology platform through application-specific subsidiaries and advancing its strategic initiatives, including the recently approved Lunar Initiatives. The company is focused on expanding the TRACER 1000's market reach, having achieved ECAC/EU G1 approval and ECAC certification for wand swabbing, and is evaluating a potential sale of 1st Detect to provide additional capital for these initiatives. Management believes the TRACER 1000 significantly outperforms currently deployed competitive trace detection solutions based on IMS technology, specifically related to false alarm rate, probability of detection, and unit up-time. The company is also focused on the AgLAB product line, with field trials demonstrating improvements in ending-weight yields by 20% or more, and the launch of the Labrador HH-GC for environmental testing. Management's strategic priorities include the continued development and commercialization of its product lines, the potential sale of 1st Detect, and the exploration of lunar resource development opportunities.

For the fiscal year ended June 30, 2026, total revenues were $1,998,734, compared to $1,758,953 in the prior fiscal year. Net loss was $4,730,000, compared to a net loss of $4,730,000 in the prior year. Diluted earnings per share was $0.00, compared to $0.00 in the prior year. The company's operating expenses included research and development expenses of $1,998,734, compared to $1,758,953 in the prior year. The company's cash and cash equivalents and investments in corporate and government debt mutual funds and ETFs are detailed in the financial statements. The company's accumulated deficit and stockholders' equity are also detailed, with the company having 2,009,050 shares of common stock issued and outstanding as of September 23, 2026. The company's financial performance reflects its ongoing investment in research and development and the commercialization of its product lines.

The company's business is subject to significant risks, including the potential failure of its strategic initiatives, particularly the Lunar Initiatives, which are in very early stages and have not been proven to be technically, financially, or commercially viable. The company currently does not have the cash or resources to fund the significant capital expenditures required for these initiatives, and its ability to obtain financing is uncertain. The company also faces intense competition from larger, better-capitalized entities, including SpaceX, Blue Origin, and Intuitive Machines, which could offer competing lunar infrastructure services at lower prices or on faster timelines. The company's reliance on government funding and support for key programs, such as the TSA approval process for the TRACER 1000, creates uncertainty, as the award processes for government programs are highly competitive and influenced by factors beyond the company's control. Additionally, the company's business is subject to risks related to the global economy, inflation, recession, and geopolitical tensions, which could impact its ability to sell products and services. The company has not identified any cybersecurity incidents that have materially affected it, but it faces risks from increased cybersecurity requirements and more sophisticated computer crime.